Kinetics of human hemopoietic cells after in vivo administration of granulocyte-macrophage colony-stimulating factor.

Abstract

The kinetic changes induced by granulocyte-macrophage colony-stimulating factor (GM-CSF) on hemopoietic cells were assessed in physiological conditions by administering GM-CSF (8 Ag/kg per d) for 3 d to nine patients with solid tumors and normal bone marrow (BM), before chemotherapy. GM-CSF increased the number of circulating granulocytes and monocytes; platelets, erythrocytes, lymphocyte number, and subsets were unmodified. GM-CSF increased the percentage of BM S phase BFU-E (from 32±7 to 79±16%), day 14 colony-forming unit granulocyte-macrophage (CFU-GM) (from 43±20 to 82±11%) and day 7 CFU-GM (from 41±14 to 56±20%). The percentage of BM myeloblasts, promyelocytes, and myelocytes in S phase increased from 26±14 to 41±6%, and that of erythroblasts increased from 25±12 to 30±12%. This suggests that GM-CSF activates both erythroid and granulomonopoietic progenitors but that, among the morphologically recognizable BM precursors, only the granulomonopoietic lineage is a direct target of the molecule. GM-CSF increased the birth rate of cycling cells from 1.3 to 3.4 cells %/h and decreased the duration of the S phase from 14.3 to 9.1 h and the cell cycle time from 86 to 26 h. After treatment discontinuation, the number of circulating granulocytes and monocytes rapidly fell. The proportion of S phase BM cells dropped to values lower than pretreatment levels, suggesting a period of relative refractoriness to cell cycle-active antineoplastic agents.

G-CSF and IL-8 but not GM-CSF correlate with severity of pulmonary neutrophilia in acute respiratory distress syndrome

“…It pro-longs the survival of eosinophils as well as neutrophils from the blood of normal volunteers in vitro by inhibiting apoptosis [18], promotes the release of monocytes, neutrophils and eosinophils from bone marrow [19] and enhances many of the biological functions of these cells [18]. However, ARDS is a disorder that specifically involves increases only in neutrophil numbers.…”

Stem cell factor leads to reduced blood processing during apheresis or the use of whole blood aliquots to support dose-intensive chemotherapy

“…3 Several growth factors have been used to mobilise PBPC, particularly G-CSF, [4][5][6] but also GM-CSF 7,8 and to a lesser extent IL-3. 9 Stem cell factor (SCF, c-kit ligand), has entered clinical trials relatively recently.…”

Hemopoietic Growth and Inhibitory Factors in Treatment of Malignancies: A review

“…Interesting attempts have been made to protect myeloid cells from the effects of cell cycle-specific agents. This was originally proposed by Aglietta et al (45,46) from a study of the cell kinetics of the response to GM-CSF. This study suggested that a short period of administration just prior to chemotherapy would enable the cytotoxic agents to be given on schedule.…”